$1.45
+0.02 (+1.40%)
USD · as of 2026-08-19 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where XCUR is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
2 interventional
Held by 2 tracked-famous managers (JANE STREET GROUP, LLC, CITADEL ADVISORS LLC) · FINRA short interest 1.0 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| Intratumoral Cavrotolimod Combined With Pembrolizumab or Cemiplimab in Patients With Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, or Other Advanced Solid TumorsNCT03684785Adverse events of cavrotolimod alone and in combination with pembrolizumab or cemiplimabRandomized · Open-label · Treatment | Phase 1/2 | Terminatedsponsor's stated reason: The study was canceled for administrative reasons. | Drug: Cavrotolimod, Cavrotolimod · Biological: Pembrolizumab, Cemiplimab | Advanced or Metastatic Merkel Cell Carcinoma, Advanced or Metastatic Cutaneous Squamous Cell Carcinoma, Advanced or Metastatic Melanoma, Advanced or Metastatic Head and Neck Squamous Cell Carcinoma, Advanced or Metastatic Solid Tumors | 57 | 2022-03-30actual | 2022-04-07 |
| A Study of AST-008 in Healthy SubjectsNCT03086278Serious related adverse eventsOpen-label · Screening | Phase 1 | Completed | Drug: AST-008 | Healthy Volunteer Study | 16 | 2018-08-16actual | 2018-09-25 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19